HENNEMAN JOHN B III 4

What Happened

• John B. Henneman III, a director of Orthofix Medical Inc. (OFIX), acquired 5,000 shares in an open-market purchase on 2026-05-07 at $12.26 per share, for a total cost of about $61,295. This was a purchase (not a sale), which some investors view as a more informative insider action than routine sales.

Key Details

• Transaction date and price: 2026-05-07 — open market purchase at $12.26/share.
• Transaction value: ~ $61,295.
• Shares owned after transaction: filing notes ownership includes 48,347 previously reported deferred stock units plus an aggregate of 2,103 shares acquired under the company’s Stock Purchase Plan; the filing excerpt does not state a single consolidated post-transaction share total.
• Footnote: the 2,103 shares were acquired under Orthofix’s Stock Purchase Plan (SPP) on 10/31/2025 and 4/30/2026; the SPP is a Rule 16b-3(b)(5) “Stock Purchase Plan” and those SPP share acquisitions are exempt from Section 16(b).
• Filing timeliness: Report covers period 2026-05-07 and was filed 2026-05-08 (filed promptly; not marked late).
• Transaction code: P = Purchase (open market/private purchase).

Context

• The purchase is modest in size (~$61k) relative to many insider trades; purchases can be seen as a positive signal but do not prove future performance.
• The filing clarifies that some holdings are deferred stock units and SPP shares (exempt acquisitions), which can affect how ownership is counted; no options were exercised and no sales or gifts were reported in this transaction.